Evidence map›Paper›PMID 40400715›Full record

ArticlebioRxiv : the preprint server for biology2025

Drug screen reveals new potent host-targeted antivirals against Mpox virus.

Arjit Vijey Jeyachandran, Anne K Zaiss, Nikhil Chakravarty, Sneha Singh, Yennifer Delgado, Ramya Paravastu, Nivedha Satheeshkumar, Ephrem Gerald, Aakash Jeysankar, Joshua Thomas and 12 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Emerging interplays between poxviruses and autophagy.Frontiers in cellular and infection microbiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Arjit Vijey JeyachandranDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.ORCID 0009-0003-5341-0804
Anne K ZaissDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Nikhil ChakravartyDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Sneha SinghDepartment of Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, MI, USA.
Yennifer DelgadoDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA, USA.
Ramya ParavastuDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Nivedha SatheeshkumarDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Ephrem GeraldDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Aakash JeysankarDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Joshua ThomasDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Lilly FullerDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Noella LeeDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Cameron TaylorCalifornia NanoSystems Institute, University of California, Los Angeles, CA, USA.
Shantanu JoshiAhmanson-Lovelace Brain Mapping Center, Department of Neurology, University of California, Los Angeles, CA, USA.ORCID 0000-0003-1287-7005
Mark ParcellsDepartment of Animal and Food Sciences, Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
Samuel W FrenchDepartment of Cellular and Molecular Pathology, University of California, Los Angeles, CA, USA.
Abhijit DateDepartment of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, USA.
Mehdi BouhaddouDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA, USA.
Gustavo GarciaDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.ORCID 0000-0002-1649-9251
Ashok KumarDepartment of Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, MI, USA.
Robert DamoiseauxDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Vaithilingaraja ArumugaswamiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicityR01DK132735 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARUMUGASWAMI, VAITHILINGARAJA, DEB, ARJUN · 2021 to 2023
$6.0M
Targeting NAD metabolism to ameliorate bacterial endophthalmitisR01EY026964 · NEI · WAYNE STATE UNIVERSITY · PI Ashok Kumar · 2017 to 2026
$3.7M
Mechanisms of Inflammation Resolution in Bacterial EndophthalmitisR01EY027381 · NEI · WAYNE STATE UNIVERSITY · PI Ashok Kumar · 2017 to 2026
$3.3M
Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infectionR01EY032149 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vaithilingaraja Arumugaswami, Ashok Kumar · 2021 to 2026
$2.8M
Developing three-dimensional antisense oligonucleotide drugs against COVID-19R01AI163216 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GUO, FENG · 2021 to 2025
$2.3M
Vitreous metabolic perturbations during bacterial and fungal endophthalmitisR01EY035499 · NEI · WAYNE STATE UNIVERSITY · PI Ashok Kumar · 2024 to 2026
$1.3M
NCI NIH HHS P30 CA016042NEI NIH HHS R01 EY026964NEI NIH HHS R01 EY027381NEI NIH HHS R01 EY032149NEI NIH HHS R01 EY035499NIAID NIH HHS R01 AI163216NIDDK NIH HHS R01 DK132735
6 · The paper itself

Abstract

Mpox virus (MPXV), a re-emerging zoonotic threat, has caused outbreaks in non-endemic regions through respiratory, sexual, and close-contact transmission. The increased transmissibility of Clade IIb fueled the 2022 global outbreak, with 2024 Clade Ib spread in the Democratic Republic of Congo further escalating concern. Both outbreaks were declared public health emergencies by the WHO. Although tecovirimat (TPOXX) has been used off-label for Mpox, its limited effectiveness highlights the critical need for newer antivirals for MPXV. We conducted high-throughput antiviral drug screening using a host-directed kinase inhibitor library composed of 2,750 compounds against 2022 Clade IIb MPXV. Our primary screen identified 138 compounds preventing MPXV cytopathic effects, including multiple inhibitors of EGFR, PI3K-mTOR, and Ras/Raf, as well as apoptosis and autophagy regulators. Secondary and tertiary screenings yielded a shortlist of potent, nontoxic antiviral compounds that inhibited MPXV replication. Three selected compounds, IRAK4-IN-6, SM-7368, and KRAS inhibitor-10, reduced MPXV-induced cell death in primary human epidermal keratinocytes. IRAK4-IN-6 and SM-7368 were also found to modulate NF-κB and STING signaling. Furthermore, these compounds were found effective in reducing skin lesions and viral burden in a mouse model of MPXV skin infection. Together, our study reveals new classes of antiviral compounds against MPXV, offering promising candidates for future clinical development.

Indexed as

antiviral agentsDNA virusKeratinocytesMonkey PoxMpox virusMPXVNF-kBOcular MpoxSignaling pathwaySmallpox

Identifiers

PMID40400715
PMCPMC12094526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.